Search Results - "Rowinsky, Eric K."

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival by Bonner, James A, Prof, Harari, Paul M, Prof, Giralt, Jordi, Prof, Cohen, Roger B, Prof, Jones, Christopher U, MD, Sur, Ranjan K, Prof, Raben, David, Prof, Baselga, Jose, Prof, Spencer, Sharon A, Prof, Zhu, Junming, PhD, Youssoufian, Hagop, MD, Rowinsky, Eric K, MD, Ang, K Kian, Prof

“…Summary Background Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in…”
Get full text

Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents by ROWINSKY, Eric K

“…Targeted induction of programmed cell death or apoptosis via the extrinsic apoptotic pathway represents an unexploited therapeutic strategy to destroy cancer…”
Get full text

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 by SPRATLIN, Jennifer L, COHEN, Roger B, MEROPOL, Neal J, LEWIS, Nancy L, CHIOREAN, E. Gabriela, FOX, Floyd, YOUSSOUFIAN, Hagop, ROWINSKY, Eric K, GAIL ECKHARDT, S, EADENS, Matthew, GORE, Lia, CAMIDGE, D. Ross, DIAB, Sami, LEONG, Stephen, O'BRYANT, Cindy, CHOW, Laura Q. M, SERKOVA, Natalie J

“…PURPOSE To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab…”
Get full text

Raf: A Strategic Target for Therapeutic Development Against Cancer by BEERAM, Muralidhar, PATNALK, Amita, ROWINSKY, Eric K

“…The mitogen-activated protein kinase (MAPK) signaling pathway plays a critical role in transmitting proliferative signals generated by cell surface receptors…”
Get full text

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck by Bonner, James A, Harari, Paul M, Giralt, Jordi, Azarnia, Nozar, Shin, Dong M, Cohen, Roger B, Jones, Christopher U, Sur, Ranjan, Raben, David, Jassem, Jacek, Ove, Roger, Kies, Merrill S, Baselga, Jose, Youssoufian, Hagop, Amellal, Nadia, Rowinsky, Eric K, Ang, K. Kian

“…Treatment of advanced locoregional head and neck cancer with high-dose radiotherapy plus cetuximab was superior to radiotherapy alone in improving local…”
Get full text

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors by MITA, Alain C, DENIS, Louis J, SEMIOND, Dorothée, BESENVAL, Michèle, TOLCHER, Anthony W, ROWINSKY, Eric K, DEBONO, Johann S, GOETZ, Andrew D, OCHOA, Leonel, FOROUZESH, Bahram, BEERAM, Muralidhar, PATNAIK, Amita, MOLPUS, Kathleen

“…Purpose: To assess the feasibility of administering XRP6258, a new taxane with a low affinity for the multidrug resistance 1 protein, as a 1-hour i.v. infusion…”
Get full text

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors by Rowinsky, Eric K

“…The overexpression and aberrant function of members of the erbB family of receptors, particularly erbB1 (also known as epidermal growth factor receptor), and…”
Get full text

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines by Lenz, Heinz-Josef, Van Cutsem, Eric, Khambata-Ford, Shirin, Mayer, Robert J, Gold, Philip, Stella, Philip, Mirtsching, Barry, Cohn, Allen L, Pippas, Andrew W, Azarnia, Nozar, Tsuchihashi, Zenta, Mauro, David J, Rowinsky, Eric K

“…This multicenter study evaluated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in…”
Get full text

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer by PEREZ-SOLER, Roman, CHACHOUA, Abraham, HAMMOND, Lisa A, ROWINSKY, Eric K, HUBERMAN, Mark, KARP, Daniel, RIGAS, James, CLARK, Gary M, SANTABARBARA, Pedro, BONOMI, Philip

“…Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. This phase II study of erlotinib in patients with…”
Get full text

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor by ROWINSKY, Eric K, YOUSSOUFIAN, Hagop, TONRA, James R, SOLOMON, Phillip, BURTRUM, Douglas, LUDWIG, Dale L

“…Targeted monoclonal antibody therapy is an important strategy in cancer therapeutics. Among the most promising characteristics of therapeutic targets are those…”
Get full text

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies by MITA, Monica M, MITA, Alain C, KNOWLES, Heather, RIVERA, Victor M, KREISBERG, Jeff, BEDROSIAN, Camille L, TOLCHER, Anthony W, CHU, Quincy S, ROWINSKY, Eric K, FETTERLY, Gerald J, GOLDSTON, Michelle, PATNAIK, Amita, MATHEWS, Lesley, RICART, Alejandro D, MAYS, Theresa

“…This phase I trial was conducted to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573;…”
Get full text

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer by HIDALGO, Manuel, BUCKNER, Jan C, ERLICHMAN, Charles, POLLACK, Marilyn S, BENI, Joseph P, DUKART, Gary, MARSHALL, Bonnie, SPEICHER, Lisa, MOORE, Laurence, ROWINSKY, Eric K

“…Purpose: Patients with advanced cancer received temsirolimus (Torisel, CCI-779), a novel inhibitor of mammalian target of rapamycin, i.v. once daily for 5 days…”
Get full text

Targeting the molecular target of rapamycin (mTOR) by Rowinsky, Eric K

“…PURPOSE OF REVIEWThe molecular target of rapamycin, which is a member of the phosphoinositide 3-kinase related kinase family and a central modulator of cell…”
Get full text

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies by Goel, Sanjay, Mita, Alain C, Mita, Monica, Rowinsky, Eric K, Chu, Quincy S, Wong, Nancy, Desjardins, Christopher, Fang, Fang, Jansen, Mendel, Shuster, Dale E, Mani, Sridhar, Takimoto, Chris H

“…Purpose: Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts…”
Get full text

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese by SPARREBOOM, Alex, WOLFF, Antonio C, MATHIJSSEN, Ron H. J, CHATELUT, Etienne, ROWINSKY, Eric K, VERWEIJ, Jaap, BAKER, Sharyn D

“…Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in clinical practice…”
Get full text

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) by SLEDGE, George W, NEUBERG, Donna, BERNARDO, Patricia, INGLE, James N, MARTINO, Silvana, ROWINSKY, Eric K, WOOD, William C

“…Between February 1993 and September 1995, 739 patients with metastatic breast cancer were entered on an Intergroup trial (E1193) comparing doxorubicin (60…”
Get full text

Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab by CURRAN, Desmond, GIRALT, Jordi, COMTE, Sylvie, BANNER, James A, HARARI, Paul M, ANG, K. Kian, COHEN, Roger B, KIES, Merrill S, JASSEM, Jacek, BASELGA, José, ROWINSKY, Eric K, AMELLAL, Nadia

“…In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck…”
Get full text

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent by Angelot-Delettre, Fanny, Roggy, Anne, Frankel, Arthur E, Lamarthee, Baptiste, Seilles, Estelle, Biichle, Sabeha, Royer, Bernard, Deconinck, Eric, Rowinsky, Eric K, Brooks, Christopher, Bardet, Valerie, Benet, Blandine, Bennani, Hind, Benseddik, Zehaira, Debliquis, Agathe, Lusina, Daniel, Roussel, Mikael, Solly, Françoise, Ticchioni, Michel, Saas, Philippe, Garnache-Ottou, Francine

“…Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of…”
Get full text

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy by YOUSSOUFIAN, Hagop, HICKLIN, Daniel J, ROWINSKY, Eric K

“…Angiogenesis is a fundamental mechanism of cancer growth and invasion. Current translational approaches are using both small-molecule inhibitors and antibodies…”
Get full text

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial by RANSON, Malcolm, HAMMOND, Lisa A, FEYEREISLOVA, Andrea, SWAISLAND, Helen, ROWINSKY, Eric K, FERRY, David, KRIS, Mark, TULLO, Andrew, MURRAY, Philip I, MILLER, Vince, AVERBUCH, Steve, OCHS, Judy, MORRIS, Charles

“…To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor…”
Get full text